Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rolling

Homestretch News

Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rolling
Breaking News: MarketsMarketsInvestment Strategy
  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 18 min. at publisher
  • 📊 Quality Score:
  • News: 68%
  • Publisher: 72%

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Nvidia vs. the rest: The markets are off to a mixed start to this holiday-shortened week. Nvidia continues to chug higher, extending its post-earnings run to about 20% and bringing its market capitalization to roughly $2.8 trillion. The Nasdaq gained 0.4%, breaking above 17,000 for the first time ever.

Jensen Huang, co-founder and CEO of Nvidia, during the Nvidia GPU Technology Conference in San Jose, California, on March 19, 2024.Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

We're trying to make sense of this crazy day on Wall Street, with the market sinking but Nvidia holding strong

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

Breaking News: Markets Markets Investment Strategy Jim Cramer NVIDIA Corp Salesforce Inc Informatica Inc Alphabet Inc Hubspot Inc Eli Lilly And Co CAVA Group Inc Abercrombie & Fitch Co Chewy Inc DICK's Sporting Goods Inc Advance Auto Parts Inc Business News

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

From Pharma's Factories Direct to YouFrom Pharma's Factories Direct to YouWhy Eli Lilly's plan to disrupt the traditional doctor-patient relationship makes us nervous.
Read more »

Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentumWhy Eli Lilly's earnings are no sure thing for traders despite obesity drug momentumThe Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter, for all but one dosage.
Read more »

Mounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly InvestmentMounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly InvestmentI cover breaking news for Forbes. Before Forbes, I worked as a reporter for USA Today in Asheville and Black Mountain, North Carolina. I received my bachelor's degree in journalism from Auburn University and my master's degree in journalism from Northwestern University.
Read more »

Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earningsEli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earningsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »



Render Time: 2025-02-12 18:09:16